Roche sales update: buying lower or selling higher, and being paid to wait

Before a company reports, options on its shares tend to cost more than in a quiet week. Whoever sells the option collects that extra.

Roche publishes its nine-month sales on Thursday 22 October 2026 at 07:00 CET, before the Swiss market opens. The shares closed at CHF 380.10, about 9% higher than after the July results (Source: Saxo price data, as of 19 October 2026). In our view, the strong Swiss franc may be the main complication for Roche: sales grew 6% in the first half, but fell 2% once converted into francs (Source: Roche half-year release, 23 July 2026).

Roche reports are rarely dramatic. Over the last eight, the shares typically moved about 2.2% on the day, and seven of the eight days were up. The one fall, 3.2%, came after the nine-month sales in October 2025 (Source: Saxo price data; Roche releases). Past performance is not indicative of future results.

Roche, with the 355 and 400 strike prices and the 20 November 2026 expiry marked. Illustrative and educational, not predictive. Past performance is not indicative of future results. Source: SaxoTrader, indicative prices, as of 19 October 2026.

A sales update, not full results

Roche publishes sales only on 22 October, without profit figures. Yet the last four sales updates moved the shares about as much as the last four full results, around 2.6% to 2.7% on average (Source: Saxo price data; Roche releases). Past performance is not indicative of future results.

Roche share price move from the previous close to the close on release day, last eight releases, against the range priced by the 20 November 2026 options (indicative Saxo quotes as of 19 October 2026). Those options run four more weeks after the report, so the band is not a one-day estimate. Past performance is not indicative of future results; figures are illustrative and not predictive. Source: Saxo price data, Roche releases, Saxo option quotes, author calculation.

What the options market expects

Option prices give a rough idea of how far the market thinks a share could move. Add the price of the call and the put with a strike closest to today’s share price. For 20 November, that points to a move of about 5.7% either way, or roughly CHF 353 to CHF 397 around the CHF 375 strike (call CHF 12.80 plus put CHF 8.75 makes about CHF 21.55, on a share price of CHF 380.10. Source: Saxo, indicative prices, as of 19 October 2026).

These options run four weeks past the report, so the 5.7% covers the report and a month of normal ups and downs, which is why it is bigger than the 2.2% typical reaction.

What happens to the option price after the report

Part of an option’s price pays for uncertainty, including the report. Once the numbers are out, that payment usually shrinks, even if the shares hardly move. Traders call this IV crush. With Roche, the report is only one day in a four-week option, so in our view the drop after 22 October may be small. A seller may not see a quick gain. Options carry a high risk of rapid loss and are not suitable for every investor.

Important note: The strategies and examples provided in this article are purely for educational purposes. They are intended to assist in shaping your thought process and should not be replicated or implemented without careful consideration. Every investor or trader must conduct their own due diligence and take into account their unique financial situation, risk tolerance, and investment objectives before making any decisions. Remember, investing in the stock market carries risk, and it’s crucial to make informed decisions.

Why the 20 November expiry

The examples use the monthly Roche options on Eurex, the European options exchange, expiring Friday 20 November 2026. Each contract covers 100 shares, priced in Swiss francs. December options add a month of risk, including a US decision on Roche’s breast cancer drug candidate giredestrant, due by 30 November (Source: Roche, 2 June 2026). One cost: the gap between the buying and selling price is about a quarter to nearly a third of the option’s price, and only 26 contracts were open at the 355 put, a sign it may be hard to trade (Source: Saxo, as of 19 October 2026).

For the investor who wants to buy Roche lower: a cash-secured put at 355

The idea: Roche is worth owning, but after the rise since July, this investor would rather buy a little lower. The seller of the put agrees to buy 100 shares at CHF 355 if Roche is below that price on 20 November. In return, the seller receives a payment today, called the premium. "Cash-secured" means the money to buy the shares is set aside.

Hypothetical, for education only. Not advice or a trade recommendation.

Example structure (illustrative only - not a trade recommendation)

• Sell 1 Roche 20 November 2026 355 put at about CHF 2.94 per share (bid 2.52, ask 3.36), with Roche at CHF 380.10
• Net credit: about CHF 294, all from the one put (CHF 2.94 on 100 shares), against CHF 35,500 of cash set aside
• Break-even at expiry: CHF 352.06, the strike less the premium, about 7.4% below the price at the time
• Maximum profit: CHF 294 (hypothetical), if Roche is at or above 355 at expiry
• Maximum risk: CHF 35,206 (hypothetical), if Roche fell to zero
• (Source: Saxo, indicative prices, as of 19 October 2026)

Why 355: it sits just inside the lower edge of the range the market expects for the month. None of the last eight reactions would have taken Roche that low in one day, but the month after the report counts too.

Risk: CHF 294 is the most the seller can earn. If Roche ends below CHF 352.06, the seller loses money, as a shareholder would. Options carry a high risk of rapid loss and are not suitable for every investor. Costs and charges apply to each leg and vary by account and venue; check the applicable rates before entering any position.

The 355 put in the SaxoTrader trade ticket, with the platform’s risk graph, max risk, max profit and break-even. Hypothetical, for education only. Past performance is not indicative of future results; figures are illustrative and not predictive. Source: SaxoTrader, as of 19 October 2026.

For the investor who already holds Roche: a covered call at 400

The idea: this investor owns Roche and would be happy to sell at CHF 400, about 5% higher. The seller of the call agrees to sell 100 shares at CHF 400 if Roche is above that price on 20 November, and receives a premium today. "Covered" means the seller already owns the shares.

Hypothetical, for education only. Not advice or a trade recommendation.

Example structure (illustrative only - not a trade recommendation)

• Own 100 Roche shares; Sell 1 Roche 20 November 2026 400 call at about CHF 3.14 per share (bid 2.76, ask 3.52), with Roche at CHF 380.10
• Net credit: about CHF 314, all from the one call (CHF 3.14 on 100 shares), around 0.8% of the CHF 38,010 share value
• Break-even at expiry: CHF 376.96, the share price less the premium
• Maximum profit: about CHF 2,304 (hypothetical) on shares and call together, if Roche is at or above 400 at expiry
• Maximum risk: CHF 37,696 (hypothetical), the share value less the premium, if Roche fell to zero
• (Source: Saxo, indicative prices, as of 19 October 2026)

Why 400: it sits just above the range the market expects for the month. Even the largest recent reaction, a 5.1% rise in July 2026, fell short of it. That is also why the premium is small.

Risk: the investor retains the full downside risk of holding the shares. The premium received provides a partial offset, but it does not protect against a significant decline in the stock price. A repeat of the 3.2% fall in October 2025 would cost about CHF 1,200 on 100 shares at today’s price, against CHF 314 received. Options carry a high risk of rapid loss and are not suitable for every investor. Costs and charges apply to each leg and vary by account and venue; check the applicable rates before entering any position.

The 400 call in the SaxoTrader trade ticket. The ticket shows the call on its own, which is why it reports unlimited risk: that applies only to a call sold without the shares. Held against 100 Roche shares, a rise above 400 is covered by the shares, and the remaining risk is a fall in the share price. Hypothetical, for education only. Past performance is not indicative of future results; figures are illustrative and not predictive. Source: SaxoTrader, as of 19 October 2026.

And if neither view fits

Both examples assume the investor wants to own Roche. Another investor may think a good quarter is already in the share price. In our view, the put may not suit that investor: CHF 294 is little comfort when buying a share that keeps falling. A holder with that view may prefer to sell some shares, or buy a put as protection, which costs money instead.

A holder who expects a strong quarter gives part of that rise away with the covered call. And doing nothing is always an option.

Worth checking before a trade:

• The gap between the buying and selling price
• How many contracts are open at that strike
• The report timing: 07:00 CET on 22 October 2026
• Commission, charged per contract
• An exit plan, decided before the report

Assignment risk note: Roche options can be exercised on any day before expiry, so a seller may have to buy or sell the shares early if the share price passes the strike. Only the seller of an option faces this.

Final thoughts

The two examples are one idea seen from both sides: the put seller names a lower price to buy at, the call seller a higher one to sell at, and both are paid for the coming month’s uncertainty. Either position can be closed early if the view changes.

Neither removes the risk of a bigger move than Roche’s history suggests. In our view, selling an option before this report may suit only an investor comfortable owning Roche after a bad day and a weak month. Options carry a high risk of rapid loss and are not suitable for every investor.

The author does not hold positions in any of the instruments mentioned in this article. The Author is permitted to wait at least 24 hours from the time of the publication before they trade the instruments themselves.